Background: Cognitive impairment is common in patients treated with hemodialysis. The trajectory of cognitive function and risk factors for cognitive decline remain uncertain in this population.
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1-3 Notably, cognitive impairment contributes to increased morbidity and mortality. 3, 4 A recent meta-analysis that incorporated many prior studies of cognitive function in patients with kidney disease confirmed poor cognitive performance in those receiving hemodialysis.
5 However, because most of these prior studies in dialysis patients are crosssectional, it remains unclear whether there is significant decline in cognitive function over time, and if so, how rapidly.
Previous longitudinal studies of dialysis patients are limited by a small number of participants and a limited array of cognitive tests.
6-8 Accordingly, there is uncertainty as to whether certain types of cognitive function, such as memory or executive function, decline at different rates. In particular, executive function, which broadly includes attention and planning, may decline faster because its pathophysiology is tied to cerebrovascular disease, 9 a common finding in hemodialysis patients. Finally, though well established in the general population, 10 it is important to establish what risk factors, including dialysis-specific risk factors, are associated with worsening cognition 1,4,11 because this knowledge is needed to implement strategies to limit cognitive decline in this vulnerable population.
We therefore assessed cognitive function using a comprehensive battery of cognitive tests at baseline and then yearly in a cohort of maintenance hemodialysis patients. We evaluated for cognitive decline and also explored risk factors for decline, focusing additionally on memory and executive function cognitive domains.
2,12 Our prespecified hypotheses, based on cross-sectional data, 2, 12 was that due to progression of vascular disease, executive function would decline more than memory and that older age and a baseline history of cardiovascular disease (CVD) would be risk factors for steeper decline.
METHODS

Study Population
Outpatients 18 years or older receiving maintenance in-center hemodialysis at 5 Dialysis Clinic Inc units and 1 hospital-based outpatient unit (St. Elizabeth's Medical Center) in the greater Boston area were screened for the Cognition and Dialysis Study, with study enrollment occurring from January 28, 2004 , through May 31, 2012 2 Eligibility criteria included English fluency and sufficient visual and hearing acuity needed to complete neurocognitive testing. To minimize floor effects and reflecting inability to provide informed consent, individuals with Mini-Mental State Examination (MMSE) scores #10 and/or advanced dementia based on medical record review were excluded. Temporary exclusion criteria included non2access-related hospitalization within 1 month of screening, receipt of hemodialysis for less than 1 month, and single-pool Kt/V (spKt/V) , 1.0. The Tufts Medical Center/Tufts University Institutional Review Board approved this study (IRB# 6409) , and all participants who completed the detailed cognitive testing signed informed consent. The clinical and research activities reported are consistent with the Declaration of Helsinki.
Baseline Demographics and Clinical Characteristics
Demographic, clinical, and laboratory factors were ascertained at the time of cognitive testing. Education information (,12th grade, high school graduate to ,2 years of college, and $2 years of college) was obtained via patient questionnaire. History of CVD, defined as a composite of either coronary artery disease and/ or peripheral vascular disease, was determined by patient history or documentation in the patient's electronic or paper chart. Patients were queried about a personal history of myocardial infarction and coronary revascularization, which were used to define coronary disease, and intermittent claudication and peripheral vascular disease, which were used to define peripheral vascular disease.
Additionally, Dialysis Clinic Inc electronic medical and paper records were reviewed for a history of these conditions, with specific focus on problem lists, hospital discharge summaries, cardiac test results, and procedure results. Additional medical history, including primary cause of ESRD, hemodialysis vascular access type, and dialysis vintage (time since hemodialysis therapy initiation), were obtained from the Dialysis Clinic Inc or St. Elizabeth's electronic record, as were mean monthly systolic and diastolic blood pressures and body mass index. Serum albumin level and spKt/V most proximate to the time of cognitive testing were obtained from participant medical records.
Neurocognitive Assessment
At study enrollment, participants were administered a battery of neurocognitive tests by research coordinators after a period of training and direct observation by the study neuropsychologist (T.S.). The same battery of tests was administered yearly to study participants when possible. To maintain quality and inter-rater reliability, testing was observed by the study neuropsychologist at 3-to 6-month intervals. To limit participant fatigue, all testing was completed during the first hour of hemodialysis. Using the same battery of tests, we have previously demonstrated similar performance regardless of whether testing was performed during the first hour of dialysis or before the start of a dialysis session.
13 When possible, neurocognitive testing was performed in a private room or in as quiet an environment as possible. The neurocognitive battery included well-validated commonly used cognitive tests (Table S1, Our prespecified primary outcomes were change in memory and executive function over time, with risk factors for decline examined as exploratory analyses. Principal component analysis with varimax rotation was used as a data reduction technique with 292 participants to derive composite scores for separate cognitive domains (memory or executive function) in the entire study population. 19 For 18 individuals who were missing baseline results on 1 cognitive test (or 2 results if derived from the same test), singleitem imputation was performed using multivariable linear regression models based on performance on other tests in the cognitive battery. Two principal components with eigenvalues greater than 2 were obtained (component 1 eigenvalue, 2.87; component 2 eigenvalue, 2.29), and the resulting component scores subsequently were used as coprimary outcomes. Using this method, all component scores have a mean of zero and standard deviation (SD) of 1. The first component was interpreted to reflect executive functioning, attention, and processing speed (referred to as executive function in the Results section), with the Trails A and B, Block Design, and Digit Symbol-Coding tests contributing significantly (Table S1 ). The second component primarily was composed of Word List Learning Recall and Recognition and was interpreted to reflect memory. Component loadings for deriving the principal component score at the baseline examination (n 5 292) were used to calculate principal component scores for follow-up testing, which included 8 patients who did not have enough data to calculate principal component analysis scores at baseline, bringing the number of unique participants up to 300.
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